Maven Capital Partners has invested £3.25m in London-based RwHealth, formerly Draper & Dash, which will lead to expansion into Manchester and Leeds.
RwHealth is a provider of predictive analytics and insights to the healthcare and pharmaceutical sectors.
The transaction includes a £1.5m investment from the Maven VCTs, £1.25m from NPIF-Maven Equity Finance, part of the Northern Powerhouse Investment Fund, and a £0.5m commitment from Maven Investor Partner Fullbrook Thorpe.
The funding will enable RwHealth to further strengthen its position in the healthcare sector while growing its footprint in the pharmaceutical market where it has already achieved strong traction in a relatively short space of time.
The business has existing relationships with a blue-chip client base, including NHS trusts, global healthcare providers and multinational pharmaceutical corporations.
The £1.25m investment from NPIF will enable RwHealth to set up a new clinical research team based across Manchester and Leeds and employ new members of its teams in the North.
RwHealth’s innovative platform delivers benefits to healthcare and pharma customers through the provision of predictive analytics and deep insights which can optimise care pathways, identify clinical variations, predict patient flows and enable best in class resource and capacity planning.
Its software solution utilises artificial intelligence (AI) and machine learning (ML) to ingest and unify data from disparate source systems including electronic medical record systems, clinical trial design systems and patient safety records.
This comprehensive linking together of information is providing clinicians with an advanced layer of insight into a patient’s journey through the healthcare system and the challenges that arise through patient flow. This enables management to adjust planning and focus accordingly and contemporaneously better diagnose sufferers of diseases.
PMSI provided CDD for the investment, including a customer referencing process, analysis of RwHealth’s market environment, competitive landscape and RTM.
2021: A PMSI Review
Despite the ongoing COVID disruptions, 2021 was a very active year in the M&A market, with PMSI able to take many positives away from it. We worked on mo...
PMSI support Stuart Turner's acquisition of a c...
Stuart Turner, a portfolio company of Epiris Fund II, has acquired Aquatronic Group Management (AGM), a provider of cold-water boosting installation and main...